Notably the reduction in PU.1 expression in bone marrow derived CD34+ HP/HSCs has been shown to induce an intermediate stage of poorly differentiated pre-leukemic cells which, with the accumulation of additional genetic mutations, results in an aggressive form of AML [147]. This evidence concerns the gene CD34 and acute myeloid leukemia.